StockData
ELDNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Eledon Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.16+0.03 (+1.41%)

Close on Oct 19, 2026

Market cap
$245.44M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 13, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 13, 2026During market hours–$-0.27–
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026During market hours–$-0.33–
Q4 FY2025
Ended Dec 31, 2025
Mar 19, 2026During market hours–––
Q3 FY2025
Ended Sep 30, 2025
Nov 14, 2025During market hours–$-0.21–
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025During market hours–$-0.13–
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025During market hours–––
Q4 FY2024
Ended Dec 31, 2024
Mar 20, 2025During market hours–––
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024During market hours–––
Q2 FY2024
Ended Jun 30, 2024
Aug 14, 2024During market hours–––
Q1 FY2024
Ended Mar 31, 2024
May 13, 2024During market hours–$-0.34–
Q4 FY2023
Ended Dec 31, 2023
Mar 28, 2024During market hours–$-0.32–

Press releases

Announcements Eledon Pharmaceuticals filed with the SEC